Advertisement

Pharmaceutical Research

, Volume 21, Issue 3, pp 436–442 | Cite as

Factors Responsible for the Variability of Saquinavir Absorption: Studies Using an Instrumented Dog Model

  • Nuzhat Tam-Zaman
  • Yun K. Tam
  • Soheir Tawfik
  • Hugh Wiltshire
Article

Abstract

Purpose. To study the effect of dose and food on the bioavailability of saquinavir in dogs.

Methods. A Youden Square block design was used for six female mongrel dogs (20-24 kg) who received six saquinavir treatments. The six randomized treatments were 1 mg/kg intravenous infusion over 30 min; 200, 400, 600, and 800 mg of saquinavir in the form of 200-mg capsules given orally with food; and 400 mg of saquinavir given orally after an overnight fast. A 200-mg 14C-saquinavir capsule was used to replace one of the 200-mg unlabeled saquinavir capsules in the 200- and 800-mg oral study.

Results. Absorption of saquinavir from the gut was variable. (FA: 49-95%). The 14C-saquinavir study shows that the total radioactivity absorbed from the gut was insignificantly different from that of unlabeled saquinavir, suggesting first-pass gut metabolism was unimportant. The bioavailability of saquinavir under fasting condition was significantly lower (8.41 ± 4.7% vs. 20.3 ± 2.6%, p < 0.05). Saquinavir underwent significant first-pass liver metabolism because hepatic clearance values (22 to 30 ml min-1kg-1) approached that of liver blood flow.

Conclusions. Incomplete gut absorption and extensive first-pass liver metabolism are the causes for low bioavailability of saquinavir in dogs. Absorption was further reduced under fasted conditions.

first-pass liver metabolism HIV protease inhibitor instrumented dog study low bioavailability poor gut absorption saquinavir 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. E. Fitzsimmons and J. M. Collins. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab. Dispos. 25:256-266 (1997).Google Scholar
  2. 2.
    V. S. Kitchen, C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, A. J. Pinching, and J. N. Weber. Safety and activity of saquinavir in HIV infection. Lancet 345:952-954 (1995).Google Scholar
  3. 3.
    S. Noble and D. Faulds. Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112 (1996).Google Scholar
  4. 4.
    C. Merry, M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tjia, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33 (1997).Google Scholar
  5. 5.
    M. Boffito, P. Carriero, L. Trentini, R. Raiteri, S. Bonora, A. Sinicco, H. E. Reynolds, P. G. Hoggard, D. J. Back, and G. Di Perri. Pharmacokinetics of saquinavir co-administered with cimetidine. J. Antimicrob. Chemother. 50:1081-1084 (2002).Google Scholar
  6. 6.
    W. Cameron, E. Sun, M. Markowitz, C. Farthing, D. McMahon, D. Poretz, C. Cohen, S. Follansbee, J. H. Mellors, A. Hsu, G. F. Granneman, R. Maki, M. Salgo, J. Court, and J. Leonard. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. In: Program and Abstracts of the XI International Conference on AIDS: July 7-12, 1996; Vancouver, British Columbia, Canada. Abstract THB 934.Google Scholar
  7. 7.
    D. W. O'Brien, H. A. Semple, G. D. Molnar, Y. K. Tam, R. T. Coutts, R. V. Rajotte, and J. Bayens-Simmonds. A chronic conscious dog model for direct transhepatic studies in normal and pancreatic islet cell transplanted dogs. J. Pharmacol. Methods 25:157-170 (1991).Google Scholar
  8. 8.
    H. R. Wiltshire, K. J. Prior, J. Dhesi, F. Trach, M. Schlageter, and H. Schöenberger. The synthesis of labeled forms of saquinavir. J. Labelled Cpd. Radiopharm. 41:1103-1126 (1998).Google Scholar
  9. 9.
    N. G. Knebel, S. R. Sharp, and M. J. Madigan. Quantification of the anti-HIV drug saquinavir by high-speed on-line high performance liquid chromatography/tandem mass spectrometry. J. Mass Spectrometry 30:1149-1156 (1995).Google Scholar
  10. 10.
    C. Ediss and Y. K. Tam. An interactive computer program for determining areas bounded by drug concentration curves using Lagrange interpolation. J. Pharmacol. Toxicol. Methods 34:165-168 (1995).Google Scholar
  11. 11.
    H. A. Semple, Y. K. Tam, and R. T. Coutts. Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model. Pharm. Res. 7:274-279 (1990).Google Scholar
  12. 12.
    A. Skerjanec, S. Tawfik, and Y. K. Tam. Nonlinear pharmacokinetics of mibefradil in the dog. J. Pharm. Sci. 85:189-192 (1996).Google Scholar
  13. 13.
    J. Alsenz, H. Steffen, and R. Alex. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 15:423-428 (1998).Google Scholar
  14. 14.
    C. B. Washington, H. R. Wiltshire, M. M. T. Moy, S. R. Harris, E. W. D. Hall, L. M. P. Weigl, Z. Liang, and T. F. Blaschke. The disposition of saquinavir in normal and P-glycoprotein deficient mice and in cultured cells. Drug Metab. Dispos. 28:1058-1062 (2000).Google Scholar
  15. 15.
    M. T. Huisman, J. W. Smit, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J. Pharmacol. Ther. 304:596-602 (2003).Google Scholar
  16. 16.
    V. D. Makhey, A. Guo, D. A. Norris, and P. Hu. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res. 15:1160-1167 (1998).Google Scholar
  17. 17.
    M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exper. Ther. 283:1552-1562 (1997).Google Scholar
  18. 18.
    C. M. Perry and S. Noble. Saquinavir: soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486 (1998).Google Scholar
  19. 19.
    V. A. Eagling, H. Wiltshire, I. W. A. Whitcombe, and D. J. Back.C. YP3A4 mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in-vitro. Xenobiotica 32:1-17 (2002).Google Scholar
  20. 20.
    H. H. T. Kupferschmidt, K. E. Fattinger, H. R. Ha, F. Follac, and S. Krädahenbühl. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:355-359 (1998).Google Scholar
  21. 21.
    K. S. Lown, D. G. Bailey, R. J. Fontana, S. K. Janardan, C. A. Adair, L. A. Fortiage, M. B. Brown, W. Guo, and P. B. Watkins. Grapefruit juice increases felodopine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:2545-2553 (1997).Google Scholar
  22. 22.
    J. L. Steimer, B. Fotteler, R. Gieschke, H. Wiltshire, and N. Buss. Predicting the optimal dose of saquinavir via modelling of dose-exposure and exposure-effect relationships. In measurement and kinetics of in vivo drug effects. In M. Danhof and J. L. Steimer (eds.), Advances in Simultaneous Pharmacokinetic/Pharmacodynamic Modelling. Center for Drug Research, Leiden/Amsterdam, 1998, pp. 79-86.Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • Nuzhat Tam-Zaman
    • 1
  • Yun K. Tam
    • 1
  • Soheir Tawfik
    • 1
  • Hugh Wiltshire
    • 2
  1. 1.Pharmacokinetics/Pharmacodynamics DepartmentKinetana Group Inc.EdmontonCanada
  2. 2.Roche Products Ltd.Welwyn Garden City, HertfordshireU.K.

Personalised recommendations